Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters:: Evaluation of the sieving coefficient

被引:22
作者
Arzuaga, A.
Isla, A.
Gascon, A. R.
Maynar, J.
Corral, E.
Pedraz, J. L.
机构
[1] Univ Basque Country, Fac Pharm, Lab Pharm & Pharmaceut Technol, ES-01006 Vitoria, Spain
[2] Santiago Apostol Hosp, Intens Care Unit, Vitoria, Spain
关键词
AN69; polysulfone; piperacillin; tazobactam; sieving coefficient; saturation coefficient; continuous venovenous hemofiltration; continuous venovenous hemodialysis; continuous renal replacement therapies; protein free fraction;
D O I
10.1159/000092921
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim: Piperacillin-tazobactam is commonly used to treat infections in ICU patients. Controversial data have been published about the sieving/saturation coefficient (Sc/Sa) of piperacillin during continuous renal replacement therapies (CRRT). The objective was to evaluate the Sc/Sa of piperacillin-tazobactam during continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodialysis (CVVHD) using AN69 and polysulfone. Methods: Ringer lactate, BSA-containing Ringer lactate and plasma were circulated at 150 ml/min. The ultrafiltrate/dialysis flow was kept at 1,500 ml/min. A bolus was injected and samples were taken. Drugs were measured using HPLC. Sc/Sa was calculated according to standard formula. Results: Free passage of drugs through the membranes was reported with protein free solutions. In the presence of proteins the Sc/Sa lowered and correlated to protein free fraction. Polysulfone had a significantly higher permeability than AN69 during CVVH. Conclusion: Drug binding to albumin contributes to the decrease of the Sc/Sa of piperacillin but it does not completely justify the in vivo value obtained by some authors. Copyright (c) 2006 S. Karger AG, Basel
引用
收藏
页码:347 / 354
页数:8
相关论文
共 42 条
  • [1] THE EFFECT OF PIPERACILLIN DOSE ON ELIMINATION KINETICS IN RENAL IMPAIRMENT
    ARONOFF, GR
    SLOAN, RS
    BRIER, ME
    LUFT, FC
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (04) : 543 - 547
  • [2] Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC
    Arzuaga, A
    Isla, A
    Gascón, AR
    Maynar, J
    Martín, A
    Solinís, MA
    Toral, D
    Pedraz, JL
    [J]. BIOMEDICAL CHROMATOGRAPHY, 2005, 19 (08) : 570 - 578
  • [3] Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous Venovenous Hemofiltration
    Arzuaga, A
    Maynar, J
    Gascón, AR
    Isla, A
    Corral, E
    Fonseca, F
    Sánchez-Izquierdo, JA
    Rello, J
    Canut, A
    Pedraz, JL
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (02) : 168 - 176
  • [4] DRUG PRESCRIBING IN RENAL-FAILURE - DOSING GUIDELINES FOR ADULTS
    BENNETT, WM
    ARONOFF, GR
    MORRISON, G
    GOLPER, TA
    PULLIAM, J
    WOLFSON, M
    SINGER, I
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1983, 3 (03) : 155 - 193
  • [5] BICKLEY SK, 1988, CLIN PHARMACY, V7, P198
  • [6] BRACHTENDORF T, 1994, CLIN NEPHROL, V42, pS3
  • [7] CLINICAL PHARMACOKINETICS DURING CONTINUOUS HEMOFILTRATION
    BRESSOLLE, F
    KINOWSKI, JM
    DELACOUSSAYE, JE
    WYNN, N
    ELEDJAM, JJ
    GALTIER, M
    [J]. CLINICAL PHARMACOKINETICS, 1994, 26 (06) : 457 - 471
  • [8] Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient's red cells
    Broadberry, RE
    Farren, TW
    Bevin, SV
    Kohler, JA
    Yates, S
    Skidmore, I
    Poole, J
    Garratty, G
    [J]. TRANSFUSION MEDICINE, 2004, 14 (01) : 53 - 57
  • [9] Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates
    Brunet, S
    Leblanc, M
    Geadah, D
    Parent, D
    Courteau, S
    Cardinal, J
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (03) : 486 - 492
  • [10] Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration
    Capellier, G
    Cornette, C
    Boillot, A
    Guinchard, C
    Jacques, T
    Blasco, G
    Barale, F
    [J]. CRITICAL CARE MEDICINE, 1998, 26 (01) : 88 - 91